These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

890 related articles for article (PubMed ID: 17310221)

  • 1. Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPAR beta/delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus.
    Mensink M; Hesselink MK; Russell AP; Schaart G; Sels JP; Schrauwen P
    Int J Obes (Lond); 2007 Aug; 31(8):1302-10. PubMed ID: 17310221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in the mitochondrial regulatory pathways constituted by the nuclear co-factors PGC-1alpha or PGC-1beta and mitofusin 2 in skeletal muscle in type 2 diabetes.
    Zorzano A; Hernández-Alvarez MI; Palacín M; Mingrone G
    Biochim Biophys Acta; 2010; 1797(6-7):1028-33. PubMed ID: 20175989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced skeletal muscle uncoupling protein-3 content in prediabetic subjects and type 2 diabetic patients: restoration by rosiglitazone treatment.
    Schrauwen P; Mensink M; Schaart G; Moonen-Kornips E; Sels JP; Blaak EE; Russell AP; Hesselink MK
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1520-5. PubMed ID: 16384852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pioglitazone treatment restores in vivo muscle oxidative capacity in a rat model of diabetes.
    Wessels B; Ciapaite J; van den Broek NM; Houten SM; Nicolay K; Prompers JJ
    Diabetes Obes Metab; 2015 Jan; 17(1):52-60. PubMed ID: 25200673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PGC-1alpha's relationship with skeletal muscle palmitate oxidation is not present with obesity despite maintained PGC-1alpha and PGC-1beta protein.
    Holloway GP; Perry CG; Thrush AB; Heigenhauser GJ; Dyck DJ; Bonen A; Spriet LL
    Am J Physiol Endocrinol Metab; 2008 Jun; 294(6):E1060-9. PubMed ID: 18349111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of prolonged fasting on AMPK signaling, gene expression, and mitochondrial respiratory chain content in skeletal muscle from lean and obese individuals.
    Wijngaarden MA; van der Zon GC; van Dijk KW; Pijl H; Guigas B
    Am J Physiol Endocrinol Metab; 2013 May; 304(9):E1012-21. PubMed ID: 23512807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome proliferator-activated receptor-gamma coactivator-1 and insulin resistance: acute effect of fatty acids.
    Hoeks J; Hesselink MK; Russell AP; Mensink M; Saris WH; Mensink RP; Schrauwen P
    Diabetologia; 2006 Oct; 49(10):2419-26. PubMed ID: 16896940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The insulin-sensitizing effect of rosiglitazone in type 2 diabetes mellitus patients does not require improved in vivo muscle mitochondrial function.
    Schrauwen-Hinderling VB; Mensink M; Hesselink MK; Sels JP; Kooi ME; Schrauwen P
    J Clin Endocrinol Metab; 2008 Jul; 93(7):2917-21. PubMed ID: 18460571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression of PPARgamma and PGC-1alpha in human omental and subcutaneous adipose tissues is related to insulin resistance markers and mediates beneficial effects of physical training.
    Ruschke K; Fishbein L; Dietrich A; Klöting N; Tönjes A; Oberbach A; Fasshauer M; Jenkner J; Schön MR; Stumvoll M; Blüher M; Mantzoros CS
    Eur J Endocrinol; 2010 Mar; 162(3):515-23. PubMed ID: 19966034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human skeletal muscle fibre type variations correlate with PPAR alpha, PPAR delta and PGC-1 alpha mRNA.
    Krämer DK; Ahlsén M; Norrbom J; Jansson E; Hjeltnes N; Gustafsson T; Krook A
    Acta Physiol (Oxf); 2006; 188(3-4):207-16. PubMed ID: 17054660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pioglitazone-induced improvements in insulin sensitivity occur without concomitant changes in muscle mitochondrial function.
    Bajpeyi S; Pasarica M; Conley KE; Newcomer BR; Jubrias SA; Gamboa C; Murray K; Sereda O; Sparks LM; Smith SR
    Metabolism; 2017 Apr; 69():24-32. PubMed ID: 28285649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retinoid X receptor expression in skeletal muscle of nondiabetic, obese and type 2 diabetic individuals.
    Codner E; Loviscach M; Ciaraldi TP; Rehman N; Carter L; Mudaliar S; Henry RR
    Metabolism; 2001 Jul; 50(7):830-4. PubMed ID: 11436190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FTO is increased in muscle during type 2 diabetes, and its overexpression in myotubes alters insulin signaling, enhances lipogenesis and ROS production, and induces mitochondrial dysfunction.
    Bravard A; Lefai E; Meugnier E; Pesenti S; Disse E; Vouillarmet J; Peretti N; Rabasa-Lhoret R; Laville M; Vidal H; Rieusset J
    Diabetes; 2011 Jan; 60(1):258-68. PubMed ID: 20943749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
    Bajaj M; Suraamornkul S; Hardies LJ; Glass L; Musi N; DeFronzo RA
    Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue-specific control of mitochondrial respiration in obesity-related insulin resistance and diabetes.
    Holmström MH; Iglesias-Gutierrez E; Zierath JR; Garcia-Roves PM
    Am J Physiol Endocrinol Metab; 2012 Mar; 302(6):E731-9. PubMed ID: 22252943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for a mitochondrial regulatory pathway defined by peroxisome proliferator-activated receptor-gamma coactivator-1 alpha, estrogen-related receptor-alpha, and mitofusin 2.
    Soriano FX; Liesa M; Bach D; Chan DC; Palacín M; Zorzano A
    Diabetes; 2006 Jun; 55(6):1783-91. PubMed ID: 16731843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subjects with early-onset type 2 diabetes show defective activation of the skeletal muscle PGC-1{alpha}/Mitofusin-2 regulatory pathway in response to physical activity.
    Hernández-Alvarez MI; Thabit H; Burns N; Shah S; Brema I; Hatunic M; Finucane F; Liesa M; Chiellini C; Naon D; Zorzano A; Nolan JJ
    Diabetes Care; 2010 Mar; 33(3):645-51. PubMed ID: 20032281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action.
    Loviscach M; Rehman N; Carter L; Mudaliar S; Mohadeen P; Ciaraldi TP; Veerkamp JH; Henry RR
    Diabetologia; 2000 Mar; 43(3):304-11. PubMed ID: 10768091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete failure of insulin-transmitted signaling, but not obesity-induced insulin resistance, impairs respiratory chain function in muscle.
    Franko A; von Kleist-Retzow JC; Böse M; Sanchez-Lasheras C; Brodesser S; Krut O; Kunz WS; Wiedermann D; Hoehn M; Stöhr O; Moll L; Freude S; Krone W; Schubert M; Wiesner RJ
    J Mol Med (Berl); 2012 Oct; 90(10):1145-60. PubMed ID: 22411022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses.
    Juurinen L; Kotronen A; Granér M; Yki-Järvinen H
    J Clin Endocrinol Metab; 2008 Jan; 93(1):118-24. PubMed ID: 17956948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.